RecallRadar

FDA Drug recall D-0137-2024

buPROPion Hydrochloride Extended-Release Tablets, USP (SR) 200 mg, 60 Tablets bottle, Distributed by: Sun Pharmaceutical Industries, Inc.,…

On 2023-12-13 the FDA classified a Class III recall of buPROPion Hydrochloride Extended-Release Tablets, USP (SR) 200 mg, 60 Tablets bottle, Distributed by: Sun Pharmaceutical Industries, Inc.,… by Sun Pharmaceutical Industries, citing failed Dissolution Specifications.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0137-2024
ClassificationClass III
Statusterminated
Initiated2023-11-22
Published2023-12-13
Last updated2026-09-13 11:52 UTC
CompanySun Pharmaceutical Industries
DistributionUS

Product

buPROPion Hydrochloride Extended-Release Tablets, USP (SR) 200 mg, 60 Tablets bottle, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited, Halol-Baroda Highway, Halol-389 350, Gujarat, India NDC 47335-738-86

Reason

Failed Dissolution Specifications

Identifiers

ndc47335-736-86
ndc47335-736-88
ndc47335-736-08
ndc47335-736-13
ndc47335-737-86
ndc47335-737-88
ndc47335-737-08
ndc47335-737-13
ndc47335-738-86
ndc47335-738-88
ndc47335-738-08
ndc47335-738-13
code_infoLot HAD0630A, exp 1/2024

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0137-2024%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.